Isoprenaline-Modified Polyethyleneimine As an Efficient Gene Delivery System for Targeted Asthma Therapy and Airway Remodeling Inhibition

Overview

Journal Biomater Res

Date 2025 Feb 3

PMID 39896757

Authors

Jiwon An

Moonhwan Choi

Sol Kim

Hyungkyung Yoon

An-Soo Jang

Sang-Kyung Lee

Taiyoun Rhim

Affiliations

Soon will be listed here.

Abstract

This study introduces a novel gene delivery system, polyethyleneimine modified with isoprenaline (PEI-isoprenaline), to enhance targeted gene delivery in the context of asthma therapy and airway remodeling. In vitro investigations used Beas2B cells to assess the biocompatibility of isoprenaline, PEI-isoprenaline, and small interfering RNA (siRNA)/PEI-isoprenaline complexes, with cytotoxicity evaluations confirming their safety. The transfection efficiency of the siRNA/PEI-isoprenaline complex was scrutinized in THP-1 cells and displayed superior performance in delivering siRNA to cells expressing the β2 adrenergic receptor (ADRB2). In vivo studies used a murine chronic asthma model to evaluate gene delivery to ADRB2-expressing cells in bronchoalveolar fluid and lung tissues. Therapeutic effects were comprehensively assessed through cell analyses, revealing substantial reductions in airway inflammatory cells and fibrosis, particularly in the Arg1 siRNA/PEI-isoprenaline group. The siRNA/PEI-isoprenaline complex exhibited an impressive 80% delivery rate, greatly surpassing the performance of polyethyleneimine 2K (20%). Notably, the complex achieved a substantial 63% reduction in arginase-1 gene expression, validating its therapeutic potential. Noteworthy inhibitory effects on airway hyperresponsiveness were observed, underscoring the complex's potential as a targeted gene delivery system for asthma treatment. Our findings underscore the promise and effectiveness of the PEI-isoprenaline complex as a gene delivery system, with its demonstrated biocompatibility, transfection efficiency, and therapeutic outcomes, including arginase-1 gene knockdown and mitigation of airway inflammation and fibrosis, indicating it as a promising candidate for advancing asthma therapy and contributing to the understanding and control of airway remodeling in respiratory diseases.

References

Billington C, Penn R . Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res. 2003; 4:2. PMC: 152647. View

Maarsingh H, Zaagsma J, Meurs H . Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol. 2009; 158(3):652-64. PMC: 2765587. DOI: 10.1111/j.1476-5381.2009.00374.x. View

Lindemann D, Racke K . Glucocorticoid inhibition of interleukin-4 (IL-4) and interleukin-13 (IL-13) induced up-regulation of arginase in rat airway fibroblasts. Naunyn Schmiedebergs Arch Pharmacol. 2003; 368(6):546-50. DOI: 10.1007/s00210-003-0839-8. View

Bratt J, Zeki A, Last J, Kenyon N . Competitive metabolism of L-arginine: arginase as a therapeutic target in asthma. J Biomed Res. 2013; 25(5):299-308. PMC: 3596726. DOI: 10.1016/S1674-8301(11)60041-9. View

Yang Z, Ming X . Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders. Front Immunol. 2014; 5:533. PMC: 4209887. DOI: 10.3389/fimmu.2014.00533. View

Elfinger M, Geiger J, Hasenpusch G, Uzgun S, Sieverling N, Aneja M . Targeting of the beta(2)-adrenoceptor increases nonviral gene delivery to pulmonary epithelial cells in vitro and lungs in vivo. J Control Release. 2009; 135(3):234-41. DOI: 10.1016/j.jconrel.2009.01.012. View

Rivera-Tirado E, Wesdemiotis C . Characterization of polyethylenimine by electrospray ionization and matrix-assisted laser desorption/ionization. J Mass Spectrom. 2011; 46(9):876-83. DOI: 10.1002/jms.1964. View

Pascual R, Peters S . The irreversible component of persistent asthma. J Allergy Clin Immunol. 2009; 124(5):883-90. PMC: 4283201. DOI: 10.1016/j.jaci.2009.09.047. View

Zhu Z, Ding J, Ma Z, Iwashina T, Tredget E . Alternatively activated macrophages derived from THP-1 cells promote the fibrogenic activities of human dermal fibroblasts. Wound Repair Regen. 2017; 25(3):377-388. DOI: 10.1111/wrr.12532. View

10.

Bousquet J, Jeffery P, Busse W, Johnson M, Vignola A . Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161(5):1720-45. DOI: 10.1164/ajrccm.161.5.9903102. View

11.

Prezelj A, Strancar J, Gubensek F, Pecar S, Degand G . Quantification of binding of some thiol-reactive clenbuterol analogues to bovine serum albumin by electron paramagnetic resonance spectroscopy. Anal Biochem. 2003; 315(2):202-7. DOI: 10.1016/s0003-2697(03)00028-9. View

12.

Klasen S, Hammermann R, Fuhrmann M, Lindemann D, Beck K, Pfeilschifter J . Glucocorticoids inhibit lipopolysaccharide-induced up-regulation of arginase in rat alveolar macrophages. Br J Pharmacol. 2001; 132(6):1349-57. PMC: 1572676. DOI: 10.1038/sj.bjp.0703951. View

13.

Cloots R, Sankaranarayanan S, Poynter M, Terwindt E, Van Dijk P, Lamers W . Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice. BMC Pulm Med. 2017; 17(1):158. PMC: 5706166. DOI: 10.1186/s12890-017-0490-7. View

14.

Levy M, Bacharier L, Bateman E, Boulet L, Brightling C, Buhl R . Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023; 33(1):7. PMC: 9907191. DOI: 10.1038/s41533-023-00330-1. View

15.

Sears M, Lotvall J . Past, present and future--beta2-adrenoceptor agonists in asthma management. Respir Med. 2005; 99(2):152-70. DOI: 10.1016/j.rmed.2004.07.003. View

16.

Engelen M, Safar A, Bartter T, Koeman F, Deutz N . Reduced arginine availability and nitric oxide synthesis in cancer is related to impaired endogenous arginine synthesis. Clin Sci (Lond). 2016; 130(14):1185-95. DOI: 10.1042/CS20160233. View

17.

Chapman D, Irvin C . Mechanisms of airway hyper-responsiveness in asthma: the past, present and yet to come. Clin Exp Allergy. 2015; 45(4):706-19. PMC: 4386586. DOI: 10.1111/cea.12506. View

18.

An S, Bai T, Bates J, Black J, Brown R, Brusasco V . Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J. 2007; 29(5):834-60. PMC: 2527453. DOI: 10.1183/09031936.00112606. View

19.

Jarjour N, Kelly E . Pathogenesis of asthma. Med Clin North Am. 2002; 86(5):925-36. DOI: 10.1016/s0025-7125(02)00087-1. View

20.

OByrne P, Bisgaard H, Godard P, Pistolesi M, Palmqvist M, Zhu Y . Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2004; 171(2):129-36. DOI: 10.1164/rccm.200407-884OC. View